Exploratory examination about the gene background to affect the stool frequency change at the Linacrotide and Elobxibat hydrate administration.

Exploratory examination about the gene background to affect the stool frequency change at the Linacrotide and Elobxibat hydrate administration. - Chronic Costipation 2020

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041200023

Enrollment

Registered

2020-06-26

Start date

2020-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic constipation

Interventions

Linacrotide and Elobxibat hydrate administration.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)A disease name: Chronic constipation 2)Form: Functional constipation 3)Age: 20 years or older 4)Sex: Regardless of men and women 5) An index of the overall status: Performance Status (ECOG) is 0 or 1 6) Written patient compliance: After the informed consent that is enough on participating to this study, an agreement by the free will of the patients is obtained.

Exclusion criteria

Exclusion criteria: 1)The patients who take irritant cathartic day after day(However, the trial entry is possible if the patients doing one-off use internal use can establish the interval for stage Washout of 2W). 2)The patients with a history of the remedy in Lubiprostone, Linaclotide, Elobixbat hydrate. 3)The patients with the serious hepatic disorder ( AST(GOT) or ALT (GPT) 100IU/L or more). 4)The patients with serious renal disease. 5)The patients with the serious systemic disease with cancer, diabetes, heart disorder, and the like. 6)The patients with the pregnant or pregnant possibility. 7)The patients who participated in other clinical trials. (clinical study) within three months before study drug beginning of dosage. 8)The patients whom an anticholinergic drug, an antipsychotic drug, anti-Parkinson medicine, opioids are given, and chemical constipation is suspected in. 9)The patients who judged a study responsibility physician or a study allotment physician to be inadequate as study patients.

Design outcomes

Primary

Measure	Time frame
A correlation between genetic polymorphism and stool frequency change at Linacrotide and Elobixibat hydrate administration.	—

Contacts

Public ContactMasakatsu Nakamura

Kanazawa Medical University

mnakamur@kanazawa-med.ac.jp+81-76-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026